Recent studies suggest a link between GLP-1 medications like Ozempic and vision loss. Learn about the risks and what you need to know if you're using these popular diabetes drugs.
In a surprising move, Lars Fruergaard Jørgensen is stepping down as CEO of Novo Nordisk after years of leading the company through a successful phase in obesity and diabetes medications. As the search for his successor begins, what does this mean for the future of the pharmaceutical giant?
